{
    "symbol": "TRVI",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-14 08:20:44",
    "content": " After reporting out positive interim cost data in the first quarter, in the second quarter we read out our prurigo nodularis trial, or PN, which was also statistically significant. This gives us cash runway into Q4 of 2023 to fund our ongoing operations, including completing the open-label extension of the PRISM trial, like Jennifer referred to, and preparing for the end of Phase 2 meeting with the FDA and planning for and conducting our next trial for chronic cough in IPF."
}